Chromium (n = 20) Placebo (n = 19)
Age (y) 47.6 ± 1.7 47.3 ± 1.7
Gender (male/female) 13/7 13/6
Race (Caucasian/African American) 7/13 6/13
BMI (kg/m2) 28.2 ± 0.8 26.9 ± 1
CD4 (count/mm3) 676 ± 78 686 ± 61
Duration of HIV Infection (y) 16.8 ± 1.4 16.3 ± 1.0
LipodystrophyScorea 2.2 ± 0.41 2.1 ± 0.41
Smokers (%) 17/20 (85%) 18/19 (94.7%)
Viral Load (copies/mL) 188 ± 67 268 ± 210
Subjects with fasting glucose ≥ 6.1 mmol/L (%) 4/20 (20%) 3/19 (15.8%)
Subjects with triglycerides ≥ 2 mmol/L (%) 6/20 (30%) 7/18 (38.9%)
Subjects with total cholesterol ≥ 5.5 mmol/L (%) 2/20 (10%) 1/18 (5.6%)
Subjects with HDL-cholesterol ≤ 0.9 mmol/L (%) 7/20 (35%) 6/18 (33.3%)
aLipodystrophyscore based physician assessment (scale 0-18)
Medications Chromium (n = 20) Placebo (n = 19)
Lipid Lowering 5/20 (25%) 1/19 (5.3%)
Cardiovascular 5/20 (25%) 3/19 (15.8%)
Antidepressant 5/20 (25%) 6/19 (31.6%)
Nucleoside Reverse Transcriptase Inhibitors 15/20 (75%) 13/19 (68.4%)
Non- Nucleoside Reverse Transcriptase Inhibitors 4/20 (20%) 2/19 (10.5%)
Protease Inhibitors 11/20 (55%) 12/19 (63.2%)
Fusion Inhibitors 1/20 (5%) 0/19 (0%)
Atripla (NNRTI + NRTI + NRTI) 4/20 (20%) 3/19 (15.8%)
Results are reported as Mean ± SEM or % of subjects. Chi-square and un-paired Student t-test were used to compare the two groups and there were no significant differences between the groups. NNRTI is non-nucleoside reverse transcriptase inhibitors; NRTI is nucleoside reverse transcriptase inhibitors.
Table 1: Subject characteristics and medications.
Goto home»